Publications by authors named "Gerald Staedtler"

Claim this Profile
A
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial.
James E Udelson, Steven R Goldsmith, Daniel Burkhoff, Pablo Colorado, Wilfried Dinh, Gerald Staedtler

Eur J Heart Fail· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.
Steven R Goldsmith, Daniel Burkhoff, Finn Gustafsson, Adriaan Voors, Faiez Zannad, Gerald Staedtler

J Card Fail· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
Tadao Akizawa, Iain C Macdougall, Jeffrey S Berns, Thomas Bernhardt, Gerald Staedtler

Am J Nephrol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Exemplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs.
Walter Wigger-Alberti, Ragna Williams, Yi-Ling von Mackensen, Maciej Hoffman-Wecker, Ulrike Grossmann, Gerald Staedtler

Skin Pharmacol Physiol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An empirically generated responder definition for rosacea treatment.
Gerald Staedtler, Kaweh Shakery, Jan Endrikat, Richard Nkulikiyinka, Christoph Gerlinger

Clin Cosmet Investig Dermatol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial.
Stephen Tyring, James A Solomon, Gerald Staedtler, Jason P Lott, Richard Nkulikiyinka

Cutis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial.
James A Solomon, Stephen Tyring, Gerald Staedtler, Meike Sand, Richard Nkulikiyinka

Cutis· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea.
Zoe Diana Draelos, Boni E Elewski, Julie C Harper, Meike Sand, Gerald Staedtler

Cutis· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study.
Zoe Diana Draelos, Boni Elewski, Gerald Staedtler, Blanka Havlickova

Cutis· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea.
James Q Del Rosso, Suzanne Bruce, Michael Jarratt, Alan Menter, Gerald Staedtler

J Drugs Dermatol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis